Cellceutix Corp(OTCMKTS:CTIX) traded around $1 when in August 2014 it started climbing upwards and saw a bullish rally in December 2014 where it touched a high of $4.8. CTIX maintained its position for a while but in January it seen to have declined to a current trading value of $3.7.
Lowest the company saw in the last 52 weeks was $1.49 and the highest at $4.93.
Cellceutix Corp(OTCMKTS:CTIX) has been keeping itself in news and On October 23rd 2014, Cellceutix announced positive top-line results for the randomized double-blind study comparing three dosing regimens of Brilacidin to daptomycin for the treatment of ABSSSI.
Cellceutix Corp(OTCMKTS:CTIX) Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antimicrobial applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix’s anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix will soon begin a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s anti-psoriasis drug Prurisol has recently completed a Phase 1 clinical trial and is being readied for a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna.
Cellceutix Corp(OTCMKTS:CTIX) a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, invites all interested parties to join the Company during its live webcast presentation at Biotech Showcase 2015 today, Monday, January 12 at 2:00 PM PT (5:00 PM ET). The conference is being held at Parc 55 Wyndham San Francisco (Union Square) in San Francisco, CA on January 12-14, 2015. Cellceutix will be presenting in Room Powell.
Cellceutix Chief Executive Officer Leo Ehrlich, will be giving an introductory overview of the programs at Cellceutix. Thereafter, Cellceutix Chief Operating Officer Dr. James Alexander, will begin with an update on Kevetrin, Cellceutix’s novel anti-cancer compound which is now starting the 10th cohort at 450 mg/m2, and will provide the status and future plans for all of the other drugs in development at Cellceutix, including Brilacidin for Acute Bacterial Skin and Skin Structure Infections, Brilacidin-OM for oral mucositis, Prurisol for psoriasis and other drugs being prepared to enter the clinical stage.
Cellceutix encourages shareholders and other investors to participate in this important presentation by accessing the live webcast through the following link: http://edge.media-server.com/m/p/ya62u49c.
Cellceutix will be publishing an archive of the event on its website under the “Events and Presentations” tab in the “Investors” section. Sign-up for email alerts to be notified immediately when the presentation is available and for all notifications on developments from the Company.
Cellceutix Corp(OTCMKTS:CTIX) wasn’t able to generate revenuefor the year ending December 31, 2013.
It has total assets of $10.85 Mand liabilities stand at $9.64 Mwith shareholder’s equity positively at $1.2 M.
Keeping in view the fundamentals, market capitalization at $422.68 Mis clearly overvalued.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...